{"prompt": "['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', '6.5.3.', 'Laboratory assays (Amended 19 October 2018)', 'Please refer to APPENDIX A for the address of the clinical laboratories used for sample', 'analysis.', \"The quality of sputum samples will be assessed at the investigator's institution and/ or at\", 'a laboratory designated by GSK Biologicals by gram staining.', 'Standard bacteriological methods (and semi-quantitative counts) will be performed on', \"fresh sputum samples at the investigator's institution and/or at a laboratory designated by\", 'GSK Biologicals. Identification of potential bacterial pathogens will be performed', 'according to agreed identification methods (potential pathogens including, but not', 'necessarily limited to, H. influenzae, S. pneumoniae, M. catarrhalis, S. aureus,', 'P. aeruginosa, K. pneumoniae and A. baumannii). All results should be entered in the', 'eCRF.', 'Further bacterial characterization for H. influenzae isolates: Identified H. influenzae', \"isolates should be collected and stored in the investigator's institution and will undergo\", 'further species confirmation (i.e. confirmed H. influenzae) and when possible, further', \"differentiation (i.e., Hi/NTHi) at GSK Biologicals' laboratory or at a laboratory\", 'designated by GSK Biologicals using molecular techniques such as PCR. Identified', \"H. influenzae isolates might undergo further testing at GSK Biologicals' laboratory or at a\", \"laboratory designated by GSK Biologicals' using other molecular techniques such as\", 'PCR and sequencing.', \"Identified M. catarrhalis isolates should be collected and stored in the investigator's\", 'institution and might undergo further species confirmation (and when possible, further', \"differentiation) at GSK Biologicals' laboratory or at a laboratory designated by GSK\", 'Biologicals using molecular techniques such as PCR and sequencing.', \"Identified P. aeruginosa isolates should be collected and stored in the investigator's\", \"institution and might potentially undergo further testing at GSK Biologicals' laboratory or\", 'at a laboratory designated by GSK Biologicals.', 'Further bacterial pathogens identification (including, but not necessarily limited to, H.', 'influenzae, S. pneumoniae, M. catarrhalis, S. pyogenes, S. aureus and P. aeruginosa) and', 'quantification (for H. influenzae, S. pneumoniae, M. catarrhalis) on stored sputum', \"samples will be performed at GSK Biologicals' laboratory or a laboratory designated by\", 'GSK Biologicals using qualitative PCR and/or quantitative PCR.', 'Viral pathogens identification (including, but not necessarily limited to, RSV,', 'parainfluenza virus, enterovirus/ HRV, metapneumovirus, influenza virus, adenovirus,', 'bocavirus and coronavirus) on stored sputum samples will be performed at GSK', \"Biologicals' laboratory or a laboratory designated by GSK Biologicals using multiplex\", 'reverse transcription polymerase chain reaction (RT-PCR).', 'In addition, some respiratory viral pathogens (such as HRV) will be quantified in stored', \"sputum samples (or subset) using RT-PCR at GSK Biologicals' laboratory or at a\", 'laboratory designated by GSK Biologicals.', '19-OCT-2018', '56', '75661ebdab2e949f7a1f1bc2071b9dec72acecci']['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'Table 8 present the methods that will be used for identification of bacterial and viral', 'pathogens.', 'Table 8', 'Microbiology', 'System', 'Component', 'Method', 'Scale', 'Laboratory', 'Quality assessment', 'Fresh sputum', 'Please refer to SPM and/or', 'Gram staining', 'Qualitative/', 'Investigator institution or', 'Central Laboratory Manual', 'semi-', 'GSK designated', 'for components tested', 'quantitative', 'laboratory', 'Bacterial pathogen identification', 'Fresh sputum', 'Respiratory bacterial', 'Standard', 'Qualitative', \"Investigator's institution\", 'pathogens', 'bacteriological', 'and/or at a laboratory', '(including H. influenzae,', 'culture and', 'Semi-', 'designated by GSK', 'S. pneumoniae,', 'standard', 'quantitative', 'Biologicals', 'M. catarrhalis, S. aureus,', 'identification', 'P. aeruginosa,', 'methods including', 'K. pneumoniae and A.', 'semi-quantitative', 'baumannii)', 'culture', 'H. influenzae', 'H. influenzae species', 'Molecular', 'Qualitative', 'GSK Biologicals', 'isolates of positive', 'confirmation and when', 'techniques such', 'laboratory* or designated', 'H. influenzae culture', 'possible Hi/NTHi', 'as differentiation', 'laboratory', 'plates', 'differentiation', 'PCR', 'Sample collection for', 'potential further', 'characterisation', 'Stored sputum', 'Respiratory bacterial', 'Multiplex PCR', 'Qualitative', 'GSK Biologicals', 'pathogens', 'and/ or quant', 'laboratory or', '(including H. influenzae,', 'itative', 'designated laboratory', 'S. pneumoniae,', 'M. catarrhalis, S. aureus and', 'P. aeruginosa,', 'Streptococcus pyogenes))', 'Viral pathogen identification', 'Stored sputum', 'Respiratory viral pathogens', 'Multiplex-PCR', 'Qualitative', 'GSK Biologicals', '(including RSV,', 'laboratory or', 'parainfluenza virus,', 'designated laboratory', 'enterovirus/ HRV,', 'metapneumovirus, influenza', 'virus, adenovirus, bocavirus', 'and coronavirus)', 'Respiratory viral pathogens', 'RT-PCR', 'Quantitative', 'GSK Biologicals', '(such as HRV)', 'laboratory* or designated', 'laboratory', '* GSK Biologicals laboratory refers to the Clinical Laboratory Sciences (CLS) in Wavre, Belgium; Rixensart, Belgium;', 'Marburg, Germany.', 'Stored frozen sputum samples (in dithiothreitol [DTT]) might be used for assay', 'development, such as assays for diagnostic purpose or for microbiome analysis and/or for', 'assay validation/characterization purpose and/or quality control.', '19-OCT-2018', '57', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']\n\n###\n\n", "completion": "END"}